Skip to main content


Fig. 3 | BMC Gastroenterology

Fig. 3

From: c-Jun N-terminal kinase activation has a prognostic implication and is negatively associated with FOXO1 activation in gastric cancer

Fig. 3

The effect of pharmacological inhibition of JNK on FOXO1 activation in cultured gastric cancer cells. (a-c). SNU-638 cells were cultured without treatment (Ctrl) or treated with DMSO vehicle control (DMSO) or SP600125 (SP) for 24 h. a Cells were treated with various concentrations of SP. Protein expressions were analyzed by Western blotting using specific antibodies against pJNKThr183/Tyr185 (pJNK), cyclin D1, pFOXO1Ser256, total FOXO1, and β-actin. b Cells were cultured in the presence or absence of SP (20 μM) and FOXO1 transcriptional activity was determined by luciferase reporter assay, which was normalized by β-galatosidase activity. Luciferase activity in Ctrl was arbitrarily set to 1 and the activities of other cells were adjusted accordingly. Each bar represents the mean ± standard deviation. * P < 0.05 compared with untreated control groups (Ctrl and DMSO). c The effect of JNK inhibition on the subcellular localization of FOXO1 was observed by double immunofluorescence staining for pJNK (green) and FOXO1 (red). 4’,6-diamidino-2-phenylindole (DAPI) staining was performed for nuclear localization (blue). d Cells were transfected with non-targeting shRNA (shCtrl) or FOXO1 shRNA (shFOXO1). The effects of FOXO1 silencing on the expressions of total FOXO1, cyclin D1, pJNK, and total JNK were evaluated by Western blotting

Back to article page